Afya Limited AFYA completed the acquisition of the total share capital of Unidom Participacoes S.A. (Unidompedro and Faculdade Dom Luiz) through its wholly-owned subsidiary Afya Participacoes S.A.
This strategic buyout will provide Afya with 300 operational medical school seats in Brazil’s Salvador city. The average purchase price of this strategic transaction was R$ 660.0 million, of which R$ 347.8 million is already paid (net debt deduction) and the remaining R$ 312.2 million will be paid in about 10 annual installments of R$31.2 million each.
The authorization request for the 300 seats was made to the Ministry of Education ("MEC") before the Mais Medicos Law was enacted and MEC concluded its analysis and issued Ordinance 630/2020. Currently, among the 300 authorized seats of Unidompedro, 125 seats are final and the remaining 175 seats are subject to a conclusion of the Ordinance 630/2020 review by the MEC upon judicial order in 2021.
If Unidompedro wins the bid processes in the Mais Medicos 3 Program, an additional payment of R$250 thousand per granted seat will be made.
Afya expects an EV/EBITDA of 4.2x upon the maturity of this transaction and beyond. In 2027, at the medical school's full maturity, expected net revenues will be R$ 267 million, of which more than 95% will be contributed by Medicine.
Price Performance
Shares of this medical education group and medical practice solutions provider in Brazil gained 21.4% in the past year compared with the Zacks Schools industry’s 46.4% growth. Although the company underperformed the industry, its focus on accretive buyouts, operational restructuring efforts and other initiatives offering top-tier medical education services will likely boost its growth in the upcoming period.
Considering the estimate revision trend, the Zacks Consensus Estimate for 2024 and second-quarter earnings per share of AFYA have, respectively, been revised upward to $1.63 from $1.56, and to 37 cents from 35 cents, in the past 30 days. The estimated figures indicate 27.3% and 27.6% year-over-year growth, respectively.
The growth trend is solidified by a VGM Score of A, backed by a Value Score and a Growth Score of A. Such an uptrend depicts analysts’ optimism about the stock’s potential.
Zacks Rank & Other Key Picks
Afya currently carries a Zacks Rank #2 (Buy).
Here are other top-ranked stocks from the Consumer Discretionary sector.
PlayAGS, Inc. AGS presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.
AGS has a trailing four-quarter earnings surprise of 40%, on average. The Zacks Consensus Estimate for AGS’ 2024 sales and earnings per share (EPS) implies growth of 7.7% and 5,166.7%, respectively, from the year-ago levels.
Adtalem Global Education Inc. ATGE currently sports a Zacks Rank of 1. ATGE has a trailing four-quarter earnings surprise of 18.8%, on average.
The consensus estimate for ATGE’s fiscal 2025 sales and EPS indicates an increase of 5.3% and 16.6%, respectively, from the year-ago levels.
La-Z-Boy Incorporated LZB currently sports a Zacks Rank of 1. LZB has a trailing four-quarter earnings surprise of 15.3%, on average.
The Zacks Consensus Estimate for LZB’s fiscal 2025 sales and EPS implies growth of 2.1% and 5%, respectively, from the year-ago levels.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
La-Z-Boy Incorporated (LZB):Free Stock Analysis Report
Adtalem Global Education Inc. (ATGE):Free Stock Analysis Report
PlayAGS, Inc. (AGS):Free Stock Analysis Report
Afya Limited (AFYA):Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
AFYA Welcomes 300 Operational Medical School Seats in Salvador
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...